Tvardi Therapeutics (TVRD) Enterprise Value (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Enterprise Value of -$25.0 million for Q1 2026, up 19.02% sequentially from -$30.8 million in Q4 2025, and up 27.08% YoY from -$19.6 million in Q1 2025.
Tvardi Therapeutics (TVRD) Enterprise Value (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Enterprise Value for 14 years, with the latest figure at -$25.0 million in Q1 2026.
- Quarterly Enterprise Value rose 27.08% year-over-year to -$25.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$25.0 million (up 27.08% YoY) and the FY2025 annual result came in at -$30.8 million, up 2.54% from the prior year.
- Enterprise Value grew to -$25.0 million in Q1 2026 per TVRD's latest filing, from -$30.8 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$25.0 million in Q1 2026 and troughed at -$157.5 million in Q2 2022.
- A 5-year average of -$69.7 million and a median of -$52.2 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value jumped 66.13% in 2023, then slumped 45.97% in 2024.
- Over 5 years, Enterprise Value stood at -$145.4 million in 2022, then soared by 64.11% to -$52.2 million in 2023, then jumped by 39.42% to -$31.6 million in 2024, then climbed by 2.54% to -$30.8 million in 2025, then increased by 19.02% to -$25.0 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$25.0 million, -$30.8 million, and -$36.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.12 Bn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | -15.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.95 Mn |
| Dec 31, 2025 | -30.81 Mn |
| Sep 30, 2025 | -36.40 Mn |
| Jun 30, 2025 | -40.95 Mn |
| Mar 31, 2025 | -34.22 Mn |
| Dec 31, 2024 | -31.61 Mn |
| Sep 30, 2024 | -38.56 Mn |
| Jun 30, 2024 | -56.62 Mn |
| Mar 31, 2024 | -69.77 Mn |
| Dec 31, 2023 | -52.18 Mn |
| Sep 30, 2023 | -63.28 Mn |
| Jun 30, 2023 | -58.66 Mn |
| Mar 31, 2023 | -47.80 Mn |
| Dec 31, 2022 | -145.40 Mn |
| Sep 30, 2022 | -155.61 Mn |
| Jun 30, 2022 | -157.51 Mn |
| Mar 31, 2022 | -141.11 Mn |
| Dec 31, 2021 | -167.04 Mn |
| Sep 30, 2021 | -144.19 Mn |
| Jun 30, 2021 | -155.18 Mn |